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61:1906–13.Regarding the Effect
of Dabigatran Plasma
ConcentrationsThe paper by Reilly et al. (1) suggested that up to 20% of patients
using the 110 and 150 mg twice daily dosing will fall outside
of the optimal concentration range of 35 to 300 ng/ml. Recently
unsealed court documents reveal internal pharmaceutical corre-
spondence that suppressed important data regarding dabigatran
therapy for patients with atrial ﬁbrillation (2,3). Corporate e-mails
suggest that the range may be narrower (3). These data were
removed from the ﬁnal paper by Reilly et al. (1) to avoid losing the
marketing advantage of being a monitor-free anticoagulant (4,5).
Given that up to 20% of patients will fall out of range and be at
risk for irreversible major bleeding or inadequate anticoagulation,
one wonders how such an omission can be justiﬁed. Pharmaceutical
companies that prioritize proﬁt over patients damage their scientiﬁc
credibility. Perhaps pulling dabigatran from hospital formularies
will send a message that clinicians will not be complicit in un-
dermining the public trust.*Rama B. Rao, MD
*Division of Emergency Medicine
Medical Toxicology
New York Presbyterian Hospital
Weill Cornell Medical College
525 East 68th Street
Box 573
New York, New York 10065
E-mail: rar2023@med.cornell.edu
http://dx.doi.org/10.1016/j.jacc.2014.02.610REFERENCES
1. Reilly PA, Lehr T, Haertter S, et al., on behalf of the RE-LY In-
vestigators. The effect of dabigatran plasma concentrations and patient
characteristics on the frequency of ischemic stroke and major bleeding in
atrial ﬁbrillation patients: the RE-LY trial (Randomized Evaluation of
Long-Term Anticoagulation Therapy). J Am Coll Cardiol 2014;63:321–8.
2. Unsealed court documents in Pradaxa case. Draft of Pradaxa research





3. Unsealed court documents in Pradaxa case. E-mail from Dr. Andreas




4. Unsealed court documents in Pradaxa case. Employee e-mail. New York
Times; February 5, 2014. Available at: http://www.nytimes.com/interactive/
2014/02/05/business/pradaxa-doc-viewer.html?&action¼click&content
Collection¼Business%20Day&module¼RelatedCoverage&region¼
Marginalia&pgtype¼article. Accessed February 13, 2014.
5. Thomas K. New emails in Pradaxa case show concern over proﬁt.
New York Times; February 7, 2014. Available at: http://www.nytimes.
com/2014/02/08/business/new-emails-in-pradaxa-case-show-concern-
over-proﬁt.html. Accessed February 13, 2014.ReplyRegarding the Effect of
Dabigatran Plasma
Concentrations
We would like to respond to Dr. Rao’s questions concerning our
paper (1). First, it is incorrect to state that any data on dabigatran and
plasma levels were suppressed. This information has been submitted
to all regulatory authorities as part of the original registration process
of dabigatran etexilate for reduction of stroke in patients with atrial
ﬁbrillation. These data have also been in the public domain since the
U.S. Food and Drug Administration (FDA) Advisory Committee
meeting in September 2010, before marketing approval (2).
Our paper, which investigated the exposure–response relation-
ship, documents plasma concentration as one factor affecting clinical
outcomes (1). Whether we could specify and defend a single
optimal concentration range for all patients was the subject of
extensive discussions among the coauthors. We ultimately came to
the conclusion that there is no single range that ﬁts all patients,
because individual patient demographics (e.g., age, renal function,
and prior stroke) are at least as important as the plasma concen-
trations in assessing beneﬁt–risk and confound the association
between drug levels and outcomes. Even with the high plasma
concentrations of dabigatran observed in patients with renal
dysfunction, the FDA has concluded there is a positive beneﬁt–
risk balance for patients (3). Further, RE-LY (Randomized Eval-
uation of Long-Term Anticoagulation Therapy) is the only trial of
a new oral anticoagulant that has published extensive data regarding
blood concentrations. It is likely that other anticoagulants will also
exhibit variability in blood concentrations.
Although it may appear attractive to monitor concentrations and
adjust dosing to improve outcomes, given the complex interactions
between plasma concentrations, demographics, and outcomes, we
cannot make recommendations on how to do this. In fact, without
routine testing in the RE-LY trial, dabigatran produces a clear net
beneﬁt over warfarin. The safety compared with warfarin has also
been conﬁrmed in post-marketing analyses by the FDA (4).*Paul A. Reilly, PhD
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